Decheng Capital LLC bought a new position in Aardvark Therapeutics, Inc. (NASDAQ:AARD - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 3,917,299 shares of the company's stock, valued at approximately $29,419,000. Aardvark Therapeutics accounts for about 8.3% of Decheng Capital LLC's holdings, making the stock its 3rd largest holding. Decheng Capital LLC owned about 18.06% of Aardvark Therapeutics as of its most recent SEC filing.
Analyst Upgrades and Downgrades
A number of brokerages have recently commented on AARD. Royal Bank Of Canada cut their price target on Aardvark Therapeutics from $21.00 to $20.00 and set an "outperform" rating for the company in a report on Thursday, May 15th. Wall Street Zen cut Aardvark Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, June 14th. Finally, HC Wainwright started coverage on Aardvark Therapeutics in a research note on Monday, June 30th. They set a "buy" rating and a $40.00 price target on the stock. One analyst has rated the stock with a sell rating and five have issued a buy rating to the company. Based on data from MarketBeat, Aardvark Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $33.00.
Check Out Our Latest Research Report on AARD
Aardvark Therapeutics Stock Performance
Shares of AARD traded up $0.12 during midday trading on Friday, hitting $12.13. The company's stock had a trading volume of 36,180 shares, compared to its average volume of 39,139. Aardvark Therapeutics, Inc. has a one year low of $4.88 and a one year high of $19.58. The company's fifty day moving average price is $12.37.
Aardvark Therapeutics (NASDAQ:AARD - Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.70) by ($0.01).
Aardvark Therapeutics Company Profile
(
Free Report)
Aardvark Therapeutics, Inc operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.
Further Reading
Before you consider Aardvark Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aardvark Therapeutics wasn't on the list.
While Aardvark Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access